secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intra-Cellular Therapies, Inc. (—)
CIK:        0001567514
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001193125-24-097845
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ITCI launches $500M stock offering; Q1 CAPLYTA sales ~$144.8M; MDD Ph3 positive
-------------------------------------------------------------------------------

- Commenced underwritten public offering of $500M common stock; underwriters have 30-day option to purchase additional 15%.
- Preliminary Q1 2024 CAPLYTA net product sales ~$144.8M; cash and equivalents ~$477M as of March 31, 2024.
- Positive Phase 3 topline results for lumateperone 42 mg as adjunctive MDD therapy: MADRS reduction -4.9 pts vs placebo (p<0.0001, ES=0.61).
- Secondary endpoint CGI-S also met (p<0.0001, ES=0.67); safety profile consistent with prior studies.
- Expect to file sNDA for MDD in H2 2024; Study 502 topline results expected late Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524097845/0001193125-24-097845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524097845/d744972d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-097845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer